A recent planned interim analysis of data from the phase III MILO study of the MEK inhibitor, binimetinib, in patients with low-grade serous ovarian cancer did not show a significant difference in PFS compared with chemotherapy, although a tumor mutation in a component of the RAS/RAF/MEK/ERK pathway was not an inclusion criterion for study enrollment [119,120]. This evidence concerns the gene MAP2K7 and ovarian serous adenocarcinoma.